Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylphenidate hydrochloride OROS
- Development stage
- Approved
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Methylphenidate hydrochloride OROS is a central nervous system (CNS) stimulant that uses the Osmotic-Controlled Release Oral Delivery System (OROS) technology for extended-release delivery. It blocks the reuptake of dopamine and noradrenaline (norepinephrine) into the presynaptic neuron, increasing the availability of these neurotransmitters in the synaptic cleft. The OROS delivery system features an osmotically active trilayer core surrounded by a semipermeable membrane with an immediate-release drug overcoat (22% of the dose) and a precision-laser drilled orifice. This provides an initial immediate release followed by controlled release over 10-12 hours, allowing for once-daily dosing.
- Brand names
- ConcertaConcerta XL
- Other names
- OROS-methylphenidatemethylphenidate ERmethylphenidate ER-C
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2B (5-Hydroxytryptamine Receptor 2B)ADRA1A (α1A)ADRA2A (α2A)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on methylphenidate hydrochloride OROS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylphenidate hydrochloride OROS.